Fig. 4: Efficacy of (+)-CBD-oct in control of chemical induced seizure.
From: Carvone derived cannabidiol enantiomers as novel anticonvulsants
a Timeline of experiment in C57Bl6 adults, red lines denote administration of vehicle or (-)-CBD or (+)-CBD-oct (20 mg*kg-1 p.o.), yellow lines denote administration of kainate (20 mg*kg-1 i.p.). b Quantification of kainate-induced (20 mg*kg-1 i.p.) seizure activity according to the Racine scale comparing 20 mg*kg-1 (-)-CBD, or (+)-CBD-oct to vehicle treated controls (Vehicle n = 13: 5.086 ± 0.409, (-)-CBD n = 8, ( + )-CBD-oct n = 13: 3.276 ± 0.409). c Survival plot of animals following seizure induction (Vehicle n = 13: survival time 44.615 ± 5.646, (-)-CBD n = 8: survival time 103.750 ± 22.547, ( + )-CBD-oct n = 13: survival time 135.385 ± 21.634; Log Rank p < 0.001, vehicle vs. (-)-CBD p = 0.0133, vehicle vs. (+)-CBD-oct p = 0.0018, (-)-CBD vs. (+)-CBD-oct p = 0.314). d Representative traces of EEG activity in wildtype mice pretreated with vehicle or (+)-CBD-oct following kainate injection (Vehicle n = 4, ( + )-CBD-oct n = 4). Yellow line denotes time of kainite administration. e Quantification of event count (Vehicle: 4.500 ± 0.577; ( + )-CBD-oct: 1.000 ± 0.000). f Time to first seizure event (Vehicle: 9.764 ± 0.476; ( + )-CBD-oct: 14.170 ± 2.853). g Time to status epilepticus (SE) (Vehicle: 10.418 ± 0.539; ( + )-CBD-oct: 15.775 ± 3.136). h Quantification of peak amplitude following kainate injection (Vehicle: 315.222 ± 98.307.; ( + )-CBD-oct: 124.308 ± 71.588). i Quantification of kainate-induced seizure activity according to the Racine scale (Gabra2-1 Vehicle n = 9: 5.189 ± 0.399, Gabra2-1 ( + )-CBD-oct n = 10: 3.576 ± 0.379). j Survival plot of animals following seizure induction (Gabra2-1 Vehicle n = 9: 42.222 ± 9.686, Gabra2-1 ( + )-CBD-oct n = 10: 102.000 ± 22.652; Log Rank p = 0.048). k Representative traces of EEG activity in Gabra2-1 mice pretreated with vehicle or (+)-CBD-oct following kainate injection. Yellow line denotes time of kainite administration. l Quantification of event count (Gabra2-1 Vehicle: 8.000 ± 2.309; Gabra2-1 ( + )-CBD-oct: 3.000 ± 1.155). m Time to first seizure event (Gabra2-1 Vehicle: 6.920 ± 0.475; Gabra2-1 ( + )-CBD-oct: 11.864 ± 3.837). n Time to status epilepticus (SE) (Gabra2-1 Vehicle: 8.653 ± 1.130; Gabra2-1 ( + )-CBD-oct: 21.508 ± 8.584). o Quantification of peak amplitude following kainate injection (Gabra2-1 Vehicle: 239.470 ± 111.917; Gabra2-1 ( + )-CBD-oct: 154.594 ± 77.503). All values listed are mean (or LS mean) ± standard error, p values from Two Way Repeated Measures ANOVA, or Two Way ANOVA, with Bonferroni post hoc; t-test, or Log Rank. Line graphs are plotted as mean, and box plots plotted as median, first and third quartile, and range.
